Another recently identified feature of patients with IGSF1 pathogenic variants [24] and demonstrated in this case is development of MASLD, likely due to obesity or suboptimally treated hypothyroidism [24]. Here, IGSF1 is linked to metabolic dysfunction-associated steatotic liver disease.